PDCD1 and graft versus host disease: This suggests that PD-1 and its ligands, PD-L1 and PD-L2, act to prevent GVHD development and that use of immune checkpoint blockade to prevent cancer in allogeneic HSCT recipients increases the risk of GVHD.